Vicore obtains SARS coronavirus patent for C21 in the USA
Gothenburg, September 22, 2021 - Vicore Pharma Holding AB (publ) (“Vicore”), a rare disease pharmaceutical company developing innovative medicines for severe lung disorders, today announces that the U.S. Patent and Trademark Office (USPTO) has granted patent number US11,123,329 covering the use of C21 to treat infections caused by Severe Acute Respiratory Syndrome (SARS) coronavirus (CoV), including SARS-CoV-2.“COVID-19 may be just a few mutations away from evading existing vaccines, and we know that even vaccinated people can both pass on the infection and become ill themselves” said Carl-